(Stroke. 2000;31:2106.)
© 2000 American Heart Association, Inc.
Original Contributions |
Secondary Stroke Prevention in Atrial Fibrillation
Lessons From Clinical Practice
From the Department of Medicine (A.E., I.P., L.K.), Guy’s, King’s & St Thomas’ School of Medicine, King’s College, London, and Queen Mary’s NHS Trust (G.Y.), Sidcup, Kent, UK.
Correspondence to Dr Andrew Evans, Department of Medicine, Guy’s, King’s & St Thomas’ School of Medicine, Denmark Hill Campus, Bessemer Road, London SE5 8PJ UK. E-mail andy.evans{at}kcl.ac.uk
Background and Purpose—Secondary prevention trials do not distinguish outcomes according to stroke cause. The purpose of the study was to determine whether trial efficacy of anticoagulation for secondary prevention could be replicated in clinical practice in strokes of different etiology.
Methods—A 2-year observation study was undertaken in 288 stroke patients with atrial fibrillation (mean age 76 years; 55% women) who were receiving anticoagulation therapy to maintain an international normalized ratio of 2.0 to 3.0. Comparisons were made of (1) patient characteristics, anticoagulation control, and annual stroke/hemorrhage rates with those of the European Atrial Fibrillation Trial and (2) cause of recurrent stroke by initial stroke subtype.
Results—Subjects were 5 years older (95% CI 3 to 7 years), and more patients had small-vessel stroke (26% versus 14%; 95% CI 3% to 17%) compared with corresponding trial data. The duration spent in the target anticoagulation range (55% versus 59%), recurrent stroke rate (5.1% versus 3.6% per year), and major (2.3% versus 2.2% per year) or minor (9.5% versus 11.8% per year) hemorrhage rates were comparable with those in patients receiving warfarin in the randomized study. Ten of 14 (71%) of embolic recurrences occurred in patients with a previous cardioembolic episode, and 8 of 11 (73%) lacunar recurrences occurred in patients with previous lacunar stroke as the qualifying event for anticoagulation (P=0.025). Only 3 of 14 cardioembolic compared with 8 of 11 lacunar recurrences occurred during adequate anticoagulation.
Conclusions—Anticoagulation for secondary stroke prevention in clinical practice achieves outcomes comparable with those of randomized trials. Nearly 26% of qualifying strokes and 40% of recurrences were nonembolic; stroke subtype should be considered when making treatment decisions.
Key Words: anticoagulation • atrial fibrillation • secondary prevention • stroke subtypes
This article has been cited by other articles:
 |
|
 |
|
  D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Ford, A. M. Choy, P. Deedwania, D. G. Karalis, C.-J. Lindholm, W. Pluta, L. Frison, S. B. Olsson, and on behalf of the SPORTIF III, V Investigators Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials Stroke, November 1, 2007; 38(11): 2965 - 2971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Hackam Predicting Stroke Risk in Patients With Atrial Fibrillation Stroke, September 1, 2007; 38(9): 2409 - 2409. [Full Text] [PDF]
|
|
|
|
|
|
D. Wallmann, D. Tuller, K. Wustmann, P. Meier, J. Isenegger, M. Arnold, H. P. Mattle, and E. Delacretaz Frequent Atrial Premature Beats Predict Paroxysmal Atrial Fibrillation in Stroke Patients: An Opportunity for a New Diagnostic Strategy Stroke, August 1, 2007; 38(8): 2292 - 2294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Oake, D. A. Fergusson, A. J. Forster, and C. van Walraven Frequency of adverse events in patients with poor anticoagulation: a meta-analysis Can. Med. Assoc. J., May 22, 2007; 176(11): 1589 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Birman-Deych, M. J. Radford, D. S. Nilasena, and B. F. Gage Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation Stroke, April 1, 2006; 37(4): 1070 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, E. M. Hylek, Y. Chang, K. A. Phillips, L. E. Henault, A. M. Capra, N. G. Jensvold, J. V. Selby, and D. E. Singer Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice? JAMA, November 26, 2003; 290(20): 2685 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bellelli, F. Guerini, A. Bianchetti, M. Trabucchi, A. Evans, and L. Kalra Anticoagulation Treatment in Disabled Patients Arch Intern Med, January 14, 2002; 162(1): 107 - 108. [Full Text] [PDF]
|
|